Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients

• Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients (Other): In this study, face-to-face patient education, giving patient education booklet, preparation of symptom management card, face-to-face and telephone counseling initiatives were planned to the experimental group.

Primary outcomes

• Change from Baseline in Symptom on the Memorial Symptom Assessment Scale at week 12 [Baseline and 12th week]: Memorial Symptom Assessment Scale (MSAS): The Memorial Symptom Assessment Scale is a multidimensional self-report questionnaire that evaluates 32 physical and psychological symptoms according to their frequency, severity and distress/bother to the person in the past week.The total score is the average of the responses to the distress scale items and and ranges from 0 to 4 with higher values indicating greater distress experienced from symptoms.
• Change from Baseline in Supportive Care Needs on the Supportive Care Needs Scale-Short Form at week 12 [Baseline and 12th week]: Supportive Care Needs Scale-Short Form: The 31-item instrument measures supportive care needs in five domains: health system and information, psychological needs, physical and daily living, patient care and support, and sexual-related. Responses are given on a scale from 1 to 5 where 1 = no help is needed and 5 = high need for help. Total scores range from 31 to 155 and higher scores indicate greater need for help.
• Change from Baseline in Self-Care Strength on the Self-Care Strength Scale at week 12 [Baseline and 12th week]: Self-Care Strength Scale: A maximum score of 140 is taken from the scale. The high score obtained from the scale indicates the high level of self-care or self-care ability and power of the individual.
• Change from Baseline in Quality of Life Level on the EORTC QLQ-C30 Quality of Life Scale(European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire) at week 12 [Baseline and 12th week]: EORTC QLQ-C30 Quality of Life Scale(European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire): This Scale was developed to measure the quality of life of patients with cancer. It includes 30 questions and three sub-dimensions: General Well-Being, Functional Difficulties, and Symptom Control. The maximum score on the scale is 100, and the minimum is 0. High scores on the functional sub-dimension indicate good/healthy functional status, high scores on the symptom sub-dimension indicate high levels of symptoms and/or problems, and high scores on the global health status/quality of life sub-dimension indicate good quality of life.
• Change from Baseline in Adverse Events on the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for 12 weeks [Baseline,for 12 weeks]: NCI-Common Terminology Criteria for Adverse Events Version 5.0: These algorithms provide support for prescribing the necessary treatment for grade 1 and grade 2 adverse events and for creating special care plans for grade 3 and 4 adverse events.

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Coming to Antalya Training and Research Hospital Medical Oncology unit for treatment,
* First time taking one of the immune checkpoint inhibitors (Ipilimumab CTLA-4, Pembrolizumab PD-1, Nivolumab PD-1, Atezolizumab PDL-1),
* Speaking and understanding Turkish,
* Being literate,
* 18 Years and older
* With solid tumor,
* No communication barrier
* Being able to communicate by phone
* Individuals who agree to participate in the research.

Exclusion Criteria:

* Patients receiving other cancer treatments in combination with immunotherapy,
* Patients with Eastern Cooperative Oncology Group Performance Scale 4.

• Fatma Arikan, Study director, Akdeniz University